Premium
Idelalisib‐Rituximab induces clinical remissions in patients with TP 53 disrupted B cell prolymphocytic leukaemia
Author(s) -
Eyre Toby A.,
Fox Christopher P.,
Shankara Paneesha,
Went Richard,
Schuh Anna H.
Publication year - 2017
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.14066
Subject(s) - idelalisib , prolymphocytic leukemia , rituximab , medicine , cancer research , immunology , leukemia , oncology , ibrutinib , lymphoma , chronic lymphocytic leukemia
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom